{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:59:25Z","timestamp":1791665965962,"version":"4.3.4"},"reference-count":34,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T00:00:00Z","timestamp":1540166400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0424-9","type":"journal-article","created":{"date-parts":[[2018,10,22]],"date-time":"2018-10-22T12:03:36Z","timestamp":1540209816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":163,"title":["Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial"],"prefix":"10.1136","volume":"6","author":[{"given":"Christophe","family":"Le Tourneau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Hoimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine","family":"Zarwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Claus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Wermke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subramanian","family":"Hariharan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"von Heydebreck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Kasturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Chand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,10,22]]},"reference":[{"key":"424_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","volume":"30","author":"E Kebebew","year":"2006","unstructured":"Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30:872\u20138.","journal-title":"World J Surg"},{"key":"424_CR2","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","volume":"29","author":"S Zheng","year":"2016","unstructured":"Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29:723\u201336.","journal-title":"Cancer Cell"},{"key":"424_CR3","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.1158\/0008-5472.CAN-16-0170","volume":"76","author":"LM Colli","year":"2016","unstructured":"Colli LM, Machiela MJ, Myers TA, Jessop L, Yu K, Chanock SJ. Burden of nonsynonymous mutations among TCGA cancers and candidate immune checkpoint inhibitor responses. Cancer Res. 2016;76:3767\u201372.","journal-title":"Cancer Res"},{"key":"424_CR4","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1210\/jc.2006-0706","volume":"92","author":"G Assi\u00e9","year":"2007","unstructured":"Assi\u00e9 G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, et al. Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2007;92:148\u201354.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"424_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cncr.24030","volume":"115","author":"Martin Fassnacht","year":"2008","unstructured":"Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer. 2009;115:243\u201350.","journal-title":"Cancer"},{"issue":"4","key":"424_CR6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ejca.2009.12.007","volume":"46","author":"Giovanni Lughezzani","year":"2010","unstructured":"Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, et al. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the International Union Against Cancer-staging system: a North American validation. Eur J Cancer. 2010;46:713\u20139.","journal-title":"European Journal of Cancer"},{"key":"424_CR7","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Neuroendocrine Tumors. V3. 2017. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf . Accessed 15 Mar 2018."},{"key":"424_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3389\/fcell.2015.00045","volume":"3","author":"R Lib\u00e9","year":"2015","unstructured":"Lib\u00e9 R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Front Cell Dev Biol. 2015;3:45.","journal-title":"Front Cell Dev Biol"},{"key":"424_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793\u2013800.","journal-title":"Nat Med"},{"key":"424_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","volume":"24","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24:207\u201312.","journal-title":"Curr Opin Immunol"},{"key":"424_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.coph.2015.05.011","volume":"23","author":"J Sunshine","year":"2015","unstructured":"Sunshine J, Taube JM. PD-1\/PD-L1 inhibitors. Curr Opin Pharmacol. 2015;23:32\u20138.","journal-title":"Curr Opin Pharmacol"},{"key":"424_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40425-015-0047-3","volume":"3","author":"AP Fay","year":"2015","unstructured":"Fay AP, Signoretti S, Callea M, Tel\u03cc GH, McKay RR, Song J, et al. Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. J Immunother Cancer. 2015;3:3.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"424_CR13","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","volume":"18","author":"Christopher R Heery","year":"2017","unstructured":"Heery CR, O\u2019Sullivan-Coyne G, Madan RA, Cordes L, Rajan A, Rauckhorst M, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18:587\u201398.","journal-title":"The Lancet Oncology"},{"key":"424_CR14","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1158\/2326-6066.CIR-15-0059","volume":"3","author":"B Boyerinas","year":"2015","unstructured":"Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3:1148\u201357.","journal-title":"Cancer Immunol Res"},{"key":"424_CR15","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","volume":"11","author":"S Khanna","year":"2016","unstructured":"Khanna S, Thomas A, Abate-Daga D, Zhang J, Morrow B, Steinberg SM, et al. Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. J Thorac Oncol. 2016;11:1993\u20132005.","journal-title":"J Thorac Oncol"},{"key":"424_CR16","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D'Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374\u201385.","journal-title":"Lancet Oncol"},{"issue":"5","key":"424_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/S1470-2045(17)30240-1","volume":"18","author":"James L Gulley","year":"2017","unstructured":"Gulley JL, Rajan A, Spigel DR, Iannotti N, Chandler J, Wong DJL, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol. 2017;18:599\u2013610.","journal-title":"The Lancet Oncology"},{"key":"424_CR18","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","volume":"35","author":"AB Apolo","year":"2017","unstructured":"Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol. 2017;35:2117\u201324.","journal-title":"J Clin Oncol"},{"key":"424_CR19","unstructured":"Bavencio (avelumab) [package insert]. Rockland, MD: EMD Serono, Inc; 2017."},{"issue":"2","key":"424_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"E.A. Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"European Journal of Cancer"},{"key":"424_CR21","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, Weber JS, Hamid O, Lebb\u00e9 C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u201320.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 7S","key":"424_CR22","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2017.35.7_suppl.96","volume":"35","author":"L Cavalcante","year":"2017","unstructured":"Cavalcante L, Carneiro BA, Costa RLB, Chae YK, Rademaker A, Giles FJ. Preliminary results from a phase II study of nivolumab for patients with metastatic adrenocortical carcinoma (ACC). J Clin Oncol. 2017;35(Suppl 7S:abstract):96.","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"424_CR23","first-page":"P424","volume":"5","author":"MA Habra","year":"2017","unstructured":"Habra MA, Campbell M, Jimenez C, Karp D, Hong D, Subbiah V, et al. Efficacy of pembrolizumab (MK-3475) in patients with adrenocortical carcinoma. J Immunother Cancer. 2017;5(Suppl 2:abstract):P424.","journal-title":"J Immunother Cancer"},{"key":"424_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1634\/theoncologist.2010-0270","volume":"16","author":"LJ Tacon","year":"2011","unstructured":"Tacon LJ, Prichard RS, Soon PS, Robinson BG, Clifton-Bligh RJ, Sidhu SB. Current and emerging therapies for advanced adrenocortical carcinoma. Oncologist. 2011;16:36\u201348.","journal-title":"Oncologist"},{"key":"424_CR25","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189\u201397.","journal-title":"N Engl J Med"},{"key":"424_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1677\/ERC-09-0281","volume":"17","author":"P Sperone","year":"2010","unstructured":"Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second\u2212\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010;17:445\u201353.","journal-title":"Endocr Relat Cancer"},{"key":"424_CR27","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","volume":"17","author":"CJ Langer","year":"2016","unstructured":"Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, et al. KEYNOTE-021 investigators. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17:1497\u2013508.","journal-title":"Lancet Oncol"},{"key":"424_CR28","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16:426\u201335.","journal-title":"Lancet Oncol"},{"key":"424_CR29","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1210\/jc.2007-2564","volume":"93","author":"M Quinkler","year":"2008","unstructured":"Quinkler M, Hahner S, Wortmann S, Johanssen S, Adam P, Ritter C, et al. Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine. J Clin Endocrinol Metab. 2008;93:2057\u201362.","journal-title":"J Clin Endocrinol Metab"},{"key":"424_CR30","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1530\/EJE-09-0804","volume":"162","author":"S Wortmann","year":"2010","unstructured":"Wortmann S, Quinkler M, Ritter C, Kroiss M, Johanssen S, Hahner S, et al. Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. Eur J Endocrinol. 2010;162:349\u201356.","journal-title":"Eur J Endocrinol"},{"key":"424_CR31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-11-0918","volume":"166","author":"A Berruti","year":"2012","unstructured":"Berruti A, Sperone P, Ferrero A, Germano A, Ardito A, Priola AM, et al. Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol. 2012;166:451\u20138.","journal-title":"Eur J Endocrinol"},{"key":"424_CR32","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1210\/jc.2013-2298","volume":"99","author":"C O\u2019Sullivan","year":"2014","unstructured":"O\u2019Sullivan C, Edgerly M, Velarde M, Wilkerson J, Venkatesan AM, Pittaluga S, et al. The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer. J Clin Endocrinol Metab. 2014;99:1291\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"424_CR33","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1210\/jc.2012-1419","volume":"97","author":"M Kroiss","year":"2012","unstructured":"Kroiss M, Quinkler M, Johanssen S, van Erp NP, Lankheet N, P\u00f6llinger A, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012;97:3495\u2013503.","journal-title":"J Clin Endocrinol Metab"},{"key":"424_CR34","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/bjc.2013.46","volume":"108","author":"A Naing","year":"2013","unstructured":"Naing A, Lorusso P, Fu S, Hong D, Chen HX, Doyle LA, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013;108:826\u201330.","journal-title":"Br J Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0424-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0424-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0424-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T14:48:57Z","timestamp":1605278937000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0424-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,22]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["424"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0424-9","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,22]]},"assertion":[{"value":"30 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial was conducted in accordance with the ethics principles of the Declaration of Helsinki and the International Council for Harmonisation Guidelines on Good Clinical Practice. The protocol was approved by the institutional review board or independent ethics committee of each center. All patients provided written informed consent before enrollment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C. Le Tourneau has served in consulting or advisory roles for Merck & Co., Bristol-Myers Squibb, Novartis, and AstraZeneca and has received honoraria from EMD Serono and AstraZeneca. C. Hoimes has served in consulting or advisory roles for Eisai and Seattle Genetics and has served on speakers bureaus for Bristol-Myers Squibb and Roche-Genentech. C. Zarwan has served in consulting or advisory roles for Perceptive Informatics and Revere Pharmaceutics. D.J. Wong has served in consulting or advisory roles for and has received honoraria from Bristol-Myers Squibb and has received research funding from Armo Biosciences, AstraZeneca\/MedImmune, BioMed Valley Discoveries, Bristol-Myers Squibb, EMD Serono, KURA Oncology, Merck & Co., and Roche-Genentech. S. Bauer has served in consulting or advisory roles for Bayer, Blueprint Medicines, Deciphera, and Eli Lilly; has received honoraria from Bayer, Novartis, GSK, Pfizer, and PharmaMar; has received research funding from Blueprint Medicines, Incyte, and Novartis; and has received reimbursement for travel and accommodation expenses from PharmaMar. R. Claus has served in consulting or advisory roles for AbbVie, Gilead, Janssen Oncology, and Roche-Genentech and has received honoraria from Janssen Oncology and Roche. M. Wermke has served in consulting or advisory roles for AstraZeneca, Bristol-Myers Squibb, Novartis, and Roche-Genentech and has received research funding from Boehringer, Celgene, Novartis, and Pfizer. S. Hariharan reports employment with and stock ownership in Pfizer. A. von Heydebreck reports employment with and stock ownership in Merck KGaA. V. Kasturi reports employment with EMD Serono. V. Chand reports employment with EMD Serono and stock ownership in Bristol-Myers Squibb. J.L. Gulley has received research funding from Astellas Medivation, Bavarian Nordic, Celgene, EMD Serono, and Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"111"}}